Pressor Effect of Recombinant Human Erythropoietin: Results of Ambulatory Blood Pressure Monitoring and Home Blood Pressure Measurements

References

• Winearls C G, Oliver D O, Pippard M J, et al. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 1986; ii: 1175–1177
   Web of Science ®Google Scholar
• Eschbach J W, Egrie J C, Downing M R, et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. New Eng J Med 1987; 316: 73–78
   PubMed Web of Science ®Google Scholar
• Casati S, Passerini P, Campise M R, et al. Benefits and risks of protracted treatment with human erythropoietin in patients having haemodialysis. Br Med J 1987; 295: 1017–1020
   PubMed Web of Science ®Google Scholar
• Bommer J, Alexiou C, Müler-Bühl U, et al. Recombinant human erythropoietin therapy in haemodialysis patients - dose determination and clinical experience. Nephrol Dial Transplant 1987; 2: 238–242
   PubMedGoogle Scholar
• Akizawa T, Koshikawa S, Takaku F, et al. Clinical effect of recombinant human erythropoietin on anemia associated with chronic renal failure. A multiinstitutional study in Japan. Internat J Artif Org 1988; 11: 343–350
   PubMed Web of Science ®Google Scholar
• Eschbach J W, Abdulhadi M H, Bowne J K, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med 1989; 111: 992–1010
   PubMed Web of Science ®Google Scholar
• Buckner F S, Eschbach J W, Haley N R, et al. Hypertension following erythropoietin therapy in anemic hemodialysis patients. Am J Hypertens 1990; 3: 947–955
   PubMed Web of Science ®Google Scholar
• Jacquot C, Ferragu-Haguet M, Lefebvre A, et al. Recombinant erythropoietin and blood pressure. Lancet 1987; ii: 1083
   Google Scholar
• Kleinert H D, Harshfield G A, Pickering T G, et al. What is the value of home blood pressure measurement in patients with mild hypertension?. Hypertension 1984; 6: 574–578
   PubMed Web of Science ®Google Scholar
• Conway J. Home blood pressure recording. Clin Exp Hypertens 1986; A8: 1247–1294
   Google Scholar
• O'Brien E, O'Malley K, Fitzgerald D. The role of home and ambulatory blood pressure recording in the management of hypertension. J Hypertens 1985; 3: 35–39
   Web of Science ®Google Scholar
• Cottier C, Julius S, Gajendragadkar S V, Schork M A. Usefullness of home BP determination in treating borderline hypertension. JAMA 1982; 248: 555–558
   PubMed Web of Science ®Google Scholar
• Pickering T G. Ambulatory monitoring and blood pressure variability. Science Press, London 1991
   Google Scholar
• O'Brien E, O'Malley K, Cox J, Stanton A. Ambulatory blood pressure monitoring in the evaluation of drug efficacy. Am Heart J 1991; 21: 999–1006
   Google Scholar
• Imai Y, Fujikura Y, Minami N, et al. Pressor effect of recombinant human erythropoietin: results of home blood pressure measurements in hemodialysis patients. Jpn J Nephrol 1994; 36: 51–56
   Google Scholar
• Yamakoshi K, Shimazu H, Shibata M, Kamiya A. New oscillometric method for indirect measurement of systolic and mean arterial pressure in the human finger. Part 1: model experiment. Med Biol Eng Comput 1982; 20: 307–313
   PubMed Web of Science ®Google Scholar
• Yamakoshi K, Shimazu H, Shibata M, kamiya A. New oscillometric method for indirect measurement of systolic and diastolic mean arterial pressure in the human finger. Part 2: correlation study. Med Biol Eng Comput 1982; 20: 314–318
   PubMed Web of Science ®Google Scholar
• Imai Y, Nihei M, Abe K, et al. A finger volume-oscillometric device for monitoring ambulatory blood pressure: laboratory and clinical evaluations. Clin Exp Hypertens 1987; A9: 2001–2025
   Google Scholar
• Imai Y, Abe K, Sasaki S, et al. Clinical evaluation of semiautomatic and automatic devices for home blood pressure measurement: comparison between cuff-oscillometric and microphone methods. J Hypertens 1989; 7: 983–990
   PubMed Web of Science ®Google Scholar
• Foti A, Kimura S, De Quatro V, Lee D. Liquid-chromatographic measurement of catecholamines and metabolites in plasma an urine. Clinical Chem 1987; 33: 2209–2213
   PubMed Web of Science ®Google Scholar
• Abe K, Otsuka Y, Saito T, et al. Measurement of plasma renin activity by agniotensin I radioimmunoassay: a modification of Haber's method. Jpn Circ J 1973; 36: 741–749
   Google Scholar
• Tsunoda K, Abe K, Goto T, et al. Effect of age on the renin-agniotensin-aldosterone system in normal subjects:simultaneous measurement of active and inactive renin, renin subtsrate, and aldosterone in plasma. J Clin Endocrinol Metab 1986; 62: 384–389
   PubMed Web of Science ®Google Scholar
• Kimura T, Abe K, Ota K, et al. Effects of acute water load, hypertonic saline infusion, and furosemide administration on atrial natriuretic peptide and vasopressin release in humans. J Clin Endorinol Metab 1986; 62: 1003–1010
   PubMed Web of Science ®Google Scholar
• Imai Y, Abe K, Sasaki S, et al. Altered circadian blood pressure rhythm in patients with Cushing's syndrome. Hypertension 1988; 12: 11–19
   PubMed Web of Science ®Google Scholar
• Imai Y, Abe K, Sasaki S, et al. Influence of age on the nocturnal fall of blood pressure and its mudulation by long-acting calcium antagonist. Clin Exp Hypertens 1990; A12: 1077–1094
   Google Scholar
• Baugart P, Walger P, Gerke M, et al. Nocturnal hypertension in renal failure, haemodialysis and after renal transplantation. J Hypertens 1989; 7: S70–S71
   Web of Science ®Google Scholar
• Portaluppi F, Montanari L, Massari M, et al. Loss of nocturnal decline of blood pressure in hypertension due to chronic renal failure. Am J Hypertens 1991; 4: 20–26
   PubMed Web of Science ®Google Scholar
• Imai Y, Abe K, Munakata M, et al. Circadian blood pressure variations under different pathophysiological conditions. J Hypertens 1990; 8: S125–S132
   Web of Science ®Google Scholar
• Khatri I M, Freis E D. Hemodynamic changes during sleep in hypertensive patients. Circulation 1969; 39: 785–790
   PubMed Web of Science ®Google Scholar
• Miller J C, Horvath S M. Cardiac output during human sleep. Aviat Space Environ Med 1976; 47: 1046–1051
   PubMed Web of Science ®Google Scholar
• Mehta S K, Walsh J T, Goldberg A D, Topham W S. Increasing daytime vascular resistance with progressive hypertension in ambulant patients. Am Heart J 1987; 113: 156–162
   PubMed Web of Science ®Google Scholar
• Mori H. Circadian variation of hemodynamics in patients with essential hypertension. J Human Hypertens 1990; 4: 384–389
   PubMed Web of Science ®Google Scholar
• Verbeenlen D, Bossuyt A, Smitz J, et al. Hemodynamics of patients with renal failure treated with recombinant human erythropoietin. Clin Nephrol 1989; 31: 6–11
   PubMed Web of Science ®Google Scholar
• Paganini E, Thomas T, Fouad F, et al. The correction of anemia in hemodialysis patients using recombinant human erythropoietin (rHuEPO), Hemodynamic effects. Kidney Int 1988; 33: 204, Abstract
   Web of Science ®Google Scholar
• London G M, Zins B, Pannier B, et al. Vascular changes in hemodialysis patients in response to recombinant human erythropoietin. Kidney Int 1989; 36: 878–882
   PubMed Web of Science ®Google Scholar
• Hori K, Onoyama K, Iseki K, Fujimi S, Fujishima M. Hemodynamic and volume changes by recombinant human erythropoietin (rHuEPO) in the treatment of anemic hemodialysis patients. Clin Nephrol 1990; 33: 293–298
   PubMed Web of Science ®Google Scholar
• Satoh K, Masuda T, Ikeda Y, et al. Hemodynamic changes by recombinant erythropoietin therapy in hemodialysis patients. Hypertension 1990; 15: 262–266
   PubMed Web of Science ®Google Scholar
• Kamata K, Marumo F, Onoyama K. Hemodynamic mechanism of the elevation in blood pressure following the improvement of anemia with recombinant human erythropoietin. Jpn Circ J 1991; 55: 649–656
   PubMedGoogle Scholar
• Tagawa H, Nagano M, Saito H, et al. Echocardiographic findings in hemodialysis patients treated with recombinant erythropoietin: proposal for a hematocrit most beneficial to hemodynamics. Clin Nephrol 1991; 35: 35–38
   PubMed Web of Science ®Google Scholar
• Nonnast-Daniel B, Creutzig A, Kühn K, et al. Effect of treatment with recombinant human erythropoietin on peripheral hemodynamics and oxygenation. Contrib Nephrol 1988; 66: 185–194
   PubMedGoogle Scholar
• Steffen H M, Brunner R, Müller R, et al. Hemodynamics, blood viscosity, and the renin-angiotensin system in hemodialysis patients under therapy with recombinant human erythropoietin. Contrib Nephrol 1989; 76: 292–298
   PubMedGoogle Scholar
• Imai Y, Abe K, Otsuka Y, et al. Blood pressure regulation in chronic hypotensive and hypertensive patients with chronic renal failure. Jpn Circ J 1981; 45: 303–314
   PubMedGoogle Scholar
• Neff M S, Kim K E, Persoff M, et al. Hemodynamics of uremic anemia. Circulation 1971; 43: 876–883
   PubMed Web of Science ®Google Scholar
• Capelli J P, Kasparian H. Cardiac work demands and left ventricular function in end-stage renal disease. Ann Intern Med 1977; 86: 261–267
   PubMed Web of Science ®Google Scholar
• Samtleben W, Baldamus C A, Bommer J, et al. Blood pressure changes during treatment with recombinant erythropoietin. Contrib Nephrol 1988; 66: 114–122
   PubMedGoogle Scholar
• Raine A EG. Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy. Lancet 1988; i: 97–100
   Google Scholar
• Canadian Erythropoietin Study Group. Effect of recombinant human erythropoietin therapy on blood pressure in hemodialysis patients. Am J Nephrol 1991; 11: 23–26
   PubMed Web of Science ®Google Scholar
• Jandeleit K, Heintz B, Gross-Heitfeld E, et al. Increased activity of the autonomic nervous system and increased sensitivity to angiotensin II infusin after therapy with recombinant human erythropoietin. Nephron 1990; 56: 220–224
   PubMedGoogle Scholar
• Heidenreich S, Rahn K H, Zidek W. Direct vasopressor effect of recombinant human erythropoietin on renal resistance vessels. Kidney Int 1991; 39: 259–265
   PubMed Web of Science ®Google Scholar
• Martin J, Moncada S. Blood pressure, erythropoietin and nitric oxide. Lancet 1988; 1: 644
   PubMed Web of Science ®Google Scholar
• Carlini R, Camberlain I, Rothstein M. IV, but not SC rHuEpo induces elevations in plasma endothelin (ET) levels in hemodialysis patients. J Am Soc Nephrol 1992; 2: 373, (Abstract)
   Google Scholar
• Takahashi K, Totsune K, Imai Y, et al. Plasma concentration of immunoreactive-endothelin in patients with chronic renal failure treated with recombinant human erythropoietin. Clin Sci 1993; 84: 47–50
   PubMed Web of Science ®Google Scholar
• Van de Borne P, Teilemans C, Vanherweghem J L, Degaute J P. Effect of recombinant human erythropoietin therapy on ambulatory blood pressure and heart rate in chronic haemodialysis patients. Nephrol Dial Transplant 1992; 7: 45–49
   PubMed Web of Science ®Google Scholar
• Report by Management Committee: The Australian therapeutic trial in mild hypertension. Lancet 1980; 1: 1261–1267
   PubMed Web of Science ®Google Scholar
• Medical Research Council Working Party. MRC trial of treatment of mild hypertension: Principal results. Br Med J 1985; 291: 97–104
   PubMed Web of Science ®Google Scholar